Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | CLO & Secretary | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,854 |
Ending reported balance
After 2026-10-02 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 340 · Balance 36,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. Row 2 · 2026-10-02 · Sale · Disposed 833 · Balance 36,021 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-02 · Sale · Disposed 1,976 · Balance 34,045 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-02 · Sale · Disposed 1,535 · Balance 32,510 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-02 · Sale · Disposed 404 · Balance 32,106 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-02 · Sale · Disposed 235 · Balance 31,871 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-02 · Sale · Disposed 17 · Balance 31,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.27 · Expires 2032-08-01 | Direct | 29,104 |
Reported balance
After 2026-10-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-02 · Exercise / conversion · Disposed 340 · Balance 29,104 F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 98 | $229.71 | $22,511.44 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,752 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.4000 to $230.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 932 | $228.75 | $213,198.45 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,850 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.4000 to $229.3000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 600 | $227.45 | $136,469.58 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,782 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $227.0400 to $227.9200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · derivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 337 | $204.50 | $68,917.38 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0100 to $204.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 963 | $203.22 | $195,702.59 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,719 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.9900 to $203.7100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 700 | $201.90 | $141,327.97 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,682 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.6500 to $202.1900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,238 | $200.94 | $248,767.31 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.6000 to $201.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,302 | $199.72 | $260,038.17 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,620 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4600 to $200.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 460 | $198.85 | $91,470.68 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,922 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.4000 to $199.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000037 · primary_doc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · derivative · entry 13 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F11 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,142 | $208.87 | $238,532.28 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 12 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,869 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F10 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.6000 to $208.9700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,446 | $208.12 | $300,939.06 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 11 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,011 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.6700 to $208.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 612 | $207.01 | $126,689.45 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 10 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,457 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.6800 to $207.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 340 | $206.37 | $70,164.78 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 9 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,069 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.6000 to $206.5400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 460 | $205.18 | $94,381.88 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,409 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.8400 to $205.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $204.17 | $40,834.00 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,869 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.8600 to $204.4800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 300 | $201.70 | $60,510.00 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,069 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 93 | $200.62 | $18,657.89 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,369 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5800 to $200.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 207 | $199.96 | $41,390.89 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,462 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.8800 to $200.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 100 | $199.01 | $19,900.50 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,669 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 100 | $197.70 | $19,769.54 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,769 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.5800 to $198.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000024 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 02, 2026 Filed Mar 28, 2026 00:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 21,525 | $0.00 Strike: $202.55 | $0.00 |
DisclosureSEC source: 0002001011-26-000032 · primary_doc.xml · derivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,525 Underlying: Common Stock · 21,525 shares Expires 2036-03-02 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2026 Filed Mar 28, 2026 00:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000032 · primary_doc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,382 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027, February 15, 2028 and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 992 | $183.83 | $182,359.36 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,869 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 801 | $183.83 | $147,247.83 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,861 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 593 | $183.83 | $109,011.19 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,662 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 4,083 | $183.83 | $750,577.89 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,255 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 8,810 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,338 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,211 | $183.83 | $590,278.13 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,528 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,928 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000013 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,739 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document |
| August 10, 2025 Filed Aug 12, 2025 20:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,325 | $150.06 | $198,829.50 |
DisclosureSEC source: 0002001011-25-000061 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,811 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 233 | $91.08 | $21,221.06 |
DisclosureSEC source: 0002001011-25-000052 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,136 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 00:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 500 | $114.08 | $57,042.15 |
DisclosureSEC source: 0002001011-25-000048 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,903 Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 500 | $114.54 | $57,270.70 |
DisclosureSEC source: 0002001011-25-000047 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,403 Read SEC document |
| May 15, 2025 Filed Jun 3, 2025 00:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,000 | $104.00 | $104,000.00 |
DisclosureSEC source: 0002001011-25-000037 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,903 F2 · balance_after: The total includes 17 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 28,043 | $0.00 Strike: $115.26 | $0.00 |
DisclosureSEC source: 0002001011-25-000016 · edgardoc.xml · derivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,043 Underlying: Common Stock · 28,043 shares Expires 2035-03-04 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,415 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000016 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,783 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 876 | $120.00 | $105,120.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,368 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,114 | $120.00 | $133,680.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,244 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,758 | $120.00 | $210,960.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,358 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,429 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,116 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,775 | $120.00 | $333,000.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,687 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,928 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000010 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,462 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). Read SEC document |
| September 23, 2024 Filed Sep 26, 2024 00:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-24-000089 · edgardoc.xml · derivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,944 Underlying: Common Stock · 2,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| September 23, 2024 Filed Sep 26, 2024 00:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,000 | $99.60 | $199,201.00 |
DisclosureSEC source: 0002001011-24-000089 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,534 Read SEC document |
| September 23, 2024 Filed Sep 26, 2024 00:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,000 | $52.27 | $104,540.00 |
DisclosureSEC source: 0002001011-24-000089 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.